DVAX earnings call for the period ending March 31, 2021.
News & Analysis: Dynavax Technologies
The company's hepatitis B vaccine wasn't its key growth driver.
Investors cheered good news from the company's COVID-19 vaccine partner.
The biotech's better-than-expected Q4 update pointed to even better days ahead.
The company's collaborations and CpG 1018 vaccine adjuvant are playing an increasingly important role.
DVAX earnings call for the period ending December 31, 2020.
The company's hepatitis B virus vaccine won European Union approval.
The biotech had lots of good news.
One is making a COVID-19 vaccine; the other is a fintech.
The company reported positive clinical results for its hepatitis B vaccine.